In breast cancer cell lines and tissues, Li et al. demonstrated that SMYD2 expressed at higher levels; furthermore, knockdown of SMYD2 in triple-negative breast cancer (TNBC) cell lines or inhibition of SMYD2 activity by AZ505 significantly reduced tumor growth in vivo. This evidence concerns the gene SMYD2 and breast carcinoma.